Your browser doesn't support javascript.
loading
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen, Howard; Smith, Stacy; Matheson, Robert T; Leonardi, Craig L; Calderon, Cesar; Brodmerkel, Carrie; Li, Katherine; Campbell, Kim; Marciniak, Stanley J; Wasfi, Yasmine; Wang, Yuhua; Szapary, Philippe; Krueger, James G.
Afiliação
  • Sofen H; Department of Medicine/Dermatology, UCLA School of Medicine, Los Angeles, Calif.
  • Smith S; Dermatology, San Diego, Calif.
  • Matheson RT; Oregon Medical Research Center, Portland, Ore.
  • Leonardi CL; Department of Dermatology, St Louis University, St Louis, Mo.
  • Calderon C; Janssen Research & Development, LLC, Spring House, Pa.
  • Brodmerkel C; Janssen Research & Development, LLC, Spring House, Pa.
  • Li K; Janssen Research & Development, LLC, Spring House, Pa.
  • Campbell K; Janssen Research & Development, LLC, Spring House, Pa.
  • Marciniak SJ; Janssen Research & Development, LLC, Spring House, Pa.
  • Wasfi Y; Janssen Research & Development, LLC, Spring House, Pa.
  • Wang Y; Janssen Research & Development, LLC, Spring House, Pa.
  • Szapary P; Janssen Research & Development, LLC, Spring House, Pa.
  • Krueger JG; Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY. Electronic address: jgk@rockefeller.edu.
J Allergy Clin Immunol ; 133(4): 1032-40, 2014 Apr.
Article em En | MEDLINE | ID: mdl-24679469

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Interleucina-23 / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Interleucina-23 / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article